معامل آبوت
Abbott Laboratories

النوع	عامة
رمز التداول	NYSE: ABT S&P 100 Component S&P 500 Component
الصناعة	الرعاية الصحية
تأسست	1888; 132 years ago (1888 (بإسم Abbott Alkaloidal Company)
المؤسس	د. والاس كالڤن آبوت
المقر الرئيسي	ليك بلف، إلينوي، الولايات المتحدة
نطاق الخدمة	جميع أنحاء العالم
أشخاص رئيسيون	مايلز وايت (رئيس مجلس الادارة وكبير الضباط التطبيقيين)
المنتجات	Branded generic drugs Medical devices Diagnostic assays منتجات تغذوية
الدخل	▲ 20.853 بليون دولار (2016)
ربح العمليات	▲ 3.185 بليون دولار (2016)
الدخل الصافي	1.4 بليون دولار (2016)
إجمالي الأصول	▲ 52.666 بليون دولار (2016)
إجمالي الأنصبة	20.538 بليون دولار (2016)
الموظفون	75,000 (2016)
Slogan	LIFE. TO THE FULLEST.
المسقط الإلكتروني	abbott.com

معامل آبوت Abbott Laboratories هي شركة رعاية صحية أمريكية عالمية. لديها 74،000 موظف وتعمل في أكثر من 150 بلدا. يقع مقر الشركة في ليك بلف، إلينوي. تأسست الشركة في شيكاغوعلى يد الطبيب "والاس كالڤن آبوت" في عام 1888 لهجريب الأدوية المعروفة. نمت الشركة لتبيع الأدوية القائمة على البحوث والأجهزة الطبية وفحوص التشخيص والمنتجات الغذائية. قامت بفصل قطاع المواد الصيدلانية القائمة على البحوث لشركة مستقلة باسم شركة آبڤي عام 2013. وفي عام 2015، بلغت الإيرادات 20.4 مليار دولار.

أبوت لديها مجموعة واسعة من الأدوية ذات العلامات التجارية العامة، والأجهزة الطبية، والتشخيص، ومنتجات التغذية. أعمال الشركة في التشخيص المخبري تنفذ فحوص الدم والمناعة. وتستخدم في الاختبارات الطبية وأنظمة أداة التشخيص في جميع أنحاء العالم من قبل المستشفيات والمختبرات وبنوك الدم، وممحرر الأطباء لتشخيص ومراقبة الأمراض مثل فيروس نقص المناعة البشرية والتهاب الكبد والسرطان وقصور القلب واضطرابات التمثيل الغذائي، وكذلك تقييم مؤشرات أخرى للصحة. في عام 1985، قامت الشركة بأول اختبار دم لفحص فيروس نقص المناعة البشرية.

تقوم نقاط أبوت الطبية للعناية بتصنيع منتجات تشخيصية لتحليل الدم لتوفير المعلومات للعاملين في مجال الرعاية الصحية والتشخيص في نقطة الرعاية للسقمى. كما توفر أبوت نقاط رعاية مقايسات القلب لغرف الطوارئ.

التاريخ

في 1888 في عمر الثلاثين، قام والاس آبوت (1857–1921)، خريج 1885 من جامعة مشيگن، بتأسيس Abbott Alkaloidal Company. في ذلك الوقت، كان يعمل طبيباً ممارساً وكان يملك صيدلية. إبداعه كان في استخدام الجزء الفعال من النباتات الطبية، التي هي عموماً شبه قلوية (مورفين، كينين، ستريكنين وكودين)، التي شكـّلها في "حبيبات ضئيلة مناسبة للجرعات". هذه المقاربة كانت ناجحة إذ أنتجت جرعات أكثر انتظاماً وفعالية للسقمى.

Abbott's first international affiliate was in London in 1907, and the company later added an affiliate in Montreal, Canada (Fact 21). Abbott started operations in Pakistan as a marketing affiliate in 1948; the company has steadily expanded to comprise a work force of over 1500 employees. Currently two manufacturing facilities located at Landhi and Korangi في كراتشي continue to produce pharmaceutical products. Expansion continued in 1962 when Abbott entered into a joint venture with Dainippon Pharmaceutical Co., Ltd., of Osaka, Japan, to manufacture radio-pharmaceuticals. In 1964, it acquired Ross Laboratories, making Ross a wholly owned subsidiary of Abbott. In 1965, Abbott's expansion in Europe continued with offices in Italy and France. Abbott Laboratories has been present in India for over 100 years through its subsidiary Abbott India Limited and it is currently India's largest healthcare products company.

According to Harvard professor Lester Grinspoon and Peter Hedblom, "في 1966 Abbott Laboratories sold the equivalent of two million doses of methamphetamine in powder form to a Long Island criminal dealer".

In 2001, the company acquired Knoll, the pharmaceutical division of BASF. In 2002, it divested the Selsun Blue brand to Chattem. Later in 2002, the company sold Clear Eyes and Murine to Prestige Brands.^[] In 2004, it spun off its hospital products division into a new 14,000 employee company named Hospira, and acquired TheraSense, a diabetes-care company, which it merged with its MediSense division to become Abbott Diabetes Care. In 2006, Abbott assisted Boston Scientific in its purchase of Guidant Corporation. As part of the agreement, Abbott purchased the vascular device division of Guidant. In 2007, Ross was renamed Abbott Nutrition.

In 2007, Abbott acquired Kos Pharmaceuticals for $3.7 billion in cash.^[] At the time of acquisition, Kos marketed Niaspan, which raises levels of “good,” or HDL, cholesterol and Advicor, a Niaspan combination drug for patients with multiple lipid disorders.

In January 2007, the company agreed to sell its in vitro diagnostics and Point-of-Care diagnostics divisions to General Electric for more than $8 billion. These units were slated to be integrated into the GE Healthcare business unit. The transaction was approved by the boards of directors of Abbott and GE and was targeted to close in the first half of 2007. However, on July 11, 2007, Abbott announced that it had terminated its agreement with GE because the parties could not agree on the terms of the deal.

On September 8, 2007, the company completed the sale of the UK manufacturing plant at Queenborough to Aesica Pharmaceuticals, a private equity-owned UK manufacturer. No announcements have been made restricting the movement of staff to Abbott unlike other sell outs. On February 26, 2009, the company completed its acquisition of Advanced Medical Optics based in Santa Ana, California. In 2009, Abbott opened a satellite research and development facility في منتزه الأبحاث، جامعة إلينوي في إربانا-شامپين.^[]

In February 2010, Abbott completed its $6.2 billion (EUR 4.5 billion) acquisition of the pharmaceuticals unit of Solvay S.A.. This provided Abbott with a large and complementary portfolio of pharmaceutical products and also expanding its presence in key emerging markets.

في 22 مارس 2010, the company completed its acquisition of a هولي‌وود، فلوريدا-based LIMS company STARLIMS. Under the terms of the deal, Abbott Laboratories acquired the company for $14 per share in an all-cash transaction valued at $123 million. On May 21, 2010, Abbott Laboratories said it would buy Piramal Healthcare Ltd.'s Healthcare Solutions unit for $2.2 billion to become the biggest drug company in India.

In October 2011, the company announced that it planned to separate into two companies, one research-based pharmaceuticals and the other in medical devices, generic drugs sold internationally, and consumer products, with device company retaining the Abbott name. The company announced that the other company would be named AbbVie in March 2012. In preparation for the reorganization, Abbott made severe budget cuts and took a $478 million charge in Q3-2012 to pay for the restructuring. The separation was effective as of January 1, 2013. AbbVie was officially listed in the New York Stock Exchange on January 2, 2013.

On May 16, 2014, it was announced that Abbott would acquire the holding company Kalo Pharma Internacional S.L. for $2.9 billion in order to secure the 73% it held of Chilean pharmaceutical company, CFR Pharmaceuticals, which the company said would more than double its branded generic drug portfolio..

In June 2014 the company entered into a definitive agreement to take over Russian pharmaceutical manufacturer Veropharm (Voronezh) in a deal worth $631 million. Abbott, which already employs 1,400 people in Russia, said it planned to set up a manufacturing presence in the country when the deal closed.

In February 2016, the company announced it would acquire Alere for $5.8 billion. In late April, of the same year, Abbott announced it would acquire St. Jude Medical for $25 billion (each share receiving $46.75 in cash & 0.8708 shares of Abbott common stock, equating to an approximate value of $85).

انظر أيضاً

• List of biotechnology companies
• List of Illinois companies
• List of pharmaceutical companies

مراجع

روابط خارجية

• abbott.com Official website

Business data

• Abbott at Google Finance
• Abbott at Google Finance
• Abbott at Yahoo Finance
• Abbott at Yahoo Finance
• Abbott at Reuters
• Abbott SEC filings at EDGAR Online
• Abbott SEC filings at the Securities and Exchange Commission